Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
| NCT ID | NCT04431635 |
| Title | Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | Big Ten Cancer Research Consortium |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| University of Illinois Cancer Center | Chicago | Illinois | 60612 | United States | Details | |
| University of Michigan Comprehensive Cancer Center | Ann Arbor | Michigan | 48109 | United States | Details | |
| University of Michigan Health System | Ann Arbor | Michigan | 48109 | United States | Details | |
| University of Nebraska Medical Center | Omaha | Nebraska | 68198 | United States | Details | |
| Rutgers Cancer Institute of New Jersey | New Brunswick | New Jersey | 08903 | United States | Details |